Development of a novel streamlined workflow (AACRE) and database (inCREDBle) for genomic analysis of carbapenem-resistant Enterobacterales.

In response to the threat of increasing antimicrobial resistance, we must increase the amount of available high-quality genomic data gathered on antibiotic-resistant bacteria. To this end, we developed an integrated pipeline for high-throughput long-read sequencing, assembly, annotation and analysis of bacterial isolates and used it to generate a large genomic data set of carbapenemase-producing Enterobacterales (CPE) isolates collected in Spain. The set of 461 isolates were sequenced with a combination of both Illumina and Oxford Nanopore Technologies (ONT) DNA sequencing technologies in order to provide genomic context for chromosomal loci and, most importantly, structural resolution of plasmids, important determinants for transmission of antimicrobial resistance.

Facile aqueous synthesis and comparative evaluation of TiO-semiconductor and TiO-metal nanohybrid photocatalysts in antibiotics degradation under visible light.

Advanced oxidation processes using TiO-based nanomaterials are sustainable technologies that hold great promise for the degradation of many types of pollutants including pharmaceutical residues. A wide variety of heterostructures coupling TiO with visible-light active nanomaterials have been explored to shift its photocatalytic properties to harness sun irradiation but a systematic comparison between them is lacking in the current literature. Furthermore, the high number of proposed nanostructures with different size, morphology, and surface area, and the often complex synthesis processes hamper the transition of these materials into commercial and effective solutions for environmental remediation.

Conservation of the enzyme-like activity and biocompatibility of CeO nanozymes in simulated body fluids.

Cerium oxide nanozymes (CeONZs) are attracting vast attention due to their antioxidant and catalytic properties and mimic the activities of multiple endogenous enzymes. However, as is the case for nanomedicines in general, the success in showing their unique medical applications has not been matched by an understanding of their pharmacokinetics, which is delaying their implementation in clinical settings. Furthermore, the data of their modifications in body fluids and the impact on their activity are scarce.